HEALTH● LOWJun 29 · Jun 29, 2026, 10:14 PM
Praxis sees encephalopathies asset relutrigine action date extended
Seeking Alpha Tech
Praxis has seen the action date for its encephalopathies asset, relutrigine, extended. This indicates a change in the regulatory timeline for the drug.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH26m agoNew World screwworm case reported in Arizona dogThe HillHEALTH48m agoThere is no other Stella for Ebola, By Azu IshiekwenePremium TimesHEALTH1h agoUS May Ease Access to Unproven PeptidesHuman ProgressHEALTH1h agoLost your spark? The "silent sister" of depression, and a quiz to spot herNPR News